SCHEMBL4112062

SCHEMBL4112062

CC(=O)c1ccc(NC(=O)Nc2ccc(C(C)C)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.69
KMT2A Q03164 7/20 0.69
RAB9A P51151 6/20 0.69
MAPT P10636 6/20 0.69
NPC1 O15118 6/20 0.69
SMN1; SMN2 Q16637 6/20 0.69
HTT P42858 1/20 0.69
NLRP1 Q9C000 1/20 0.69
TAAR1 Q96RJ0 1/20 0.66
CA12 O43570 4/20 0.59
CA1 P00915 4/20 0.59
CA2 P00918 4/20 0.59
CA9 Q16790 4/20 0.59
TP53 P04637 3/20 0.58
ALDH1A1 P00352 2/20 0.58
MAPK1 P28482 2/20 0.58
THRB P10828 1/20 0.58
PANK3 Q9H999 1/20 0.58
LMNA P02545 3/20 0.57
POLB P06746 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19707622 0.89 RAB9A (0.76) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL3633396 0.87 NPC1 (0.84) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL4112698 0.85 KMT2A (0.71) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL182327 0.84 CYP2C9 (0.55) MEN1KMT2ARAB9AMAPTNPC1
Hydrochloric Acid SCHEMBL5197216 0.82 CYP2C9 (0.53) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL4105821 0.81 RAB9A (0.67) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL22588926 0.81 RAB9A (0.67) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL4111833 0.81 MEN1 (1.00) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL4117858 0.81 RAB9A (0.67) MEN1KMT2ARAB9AMAPTNPC1
SCHEMBL4111411 0.81 MEN1 (0.67) MEN1KMT2ARAB9AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MEN1 3273/4885KMT2A 2807/4885RAB9A 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.